Methods of manufacture of immunocompatible amniotic membrane products
AssigneeOsiris Therapeutics, Inc.
InventorsSamson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
Life of this patent
Estimating the term…
Abstract
Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.
Claims17
A method of cryopreserving an amniotic membrane comprising the steps of:
- a. obtaining a placenta comprising an amniotic membrane;
- b. isolating the amniotic membrane from the placenta;
- c. selectively depleting the amniotic membrane of a substantial portion of one or more types of functional immunogenic cells by
- i. incubating the amniotic membrane in a cryopreservation medium at a temperature of about 2° C. to about 8° C. for at least 30 minutes;
- followed directly by
- ii. cryopreserving the amniotic membrane in the cryopreservation medium at about −80° C.;
- wherein the amniotic membrane comprises at least 70% viable therapeutic cells, wherein the viable therapeutic cells are native to the amniotic membrane;
- wherein the viable cells comprise two or more cell types consisting of MSCs, fibroblasts, and epithelial cells;
- and wherein said selectively depleting step kills or inactivates functional CD14+macrophages.
Dependencies are inferred from the claim text.